Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUBMN5)

Drug Name

BIBV 308 Drug Info

Synonyms

Terbogrel; UNII-5Z4KWQ5OGN; 149979-74-8; 5Z4KWQ5OGN; CHEMBL281398; Terbogrel [USAN:INN]; BIBV 308 SE; Terbogrel (USAN/INN); AC1O6AAX; SCHEMBL42848; BIBV-308-SE; SCHEMBL15413063; ZINC11726169; BDBM50075624; DB12204; CS-6743; (5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((Cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid; HY-19189; D06077; L001474; 6-{3-[1-(tert-butylamino)-2-cyano-(E)-1-iminomethylamino]phenyl}-6-(3-pyridyl)-(E)-5-hexenoic acid

Indication

Disease Entry	ICD 11	Status	REF
Peripheral vascular disease	BD4Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 6449876
CAS Number: CAS 149979-74-8
TTD Drug ID: DMUBMN5

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Thromboxane A2 receptor (TBXA2R)	DTT	TBXA2R	6.075	5.925	6.729	6.096

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Peripheral vascular disease

ICD Disease Classification

BD4Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Thromboxane A2 receptor (TBXA2R)	DTT	TBXA2R	2.78E-04	-0.11	-0.31

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02223013) Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects. U.S. National Institutes of Health.
2	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.